Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efocipegtrutide - Hanmi Pharmaceutical

Drug Profile

Efocipegtrutide - Hanmi Pharmaceutical

Alternative Names: GLP-1/GIP/glucagon triagonist - Hanmi Pharmaceutical; HM-15211; LAPS-triple agonist

Latest Information Update: 27 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antidementias; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Antiparkinsonians; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis; Idiopathic pulmonary fibrosis; Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Phase I Non-alcoholic fatty liver disease
  • Preclinical Hepatic fibrosis; Idiopathic pulmonary fibrosis
  • Discontinued Alzheimer's disease; Dyslipidaemias; Multiple sclerosis; Obesity; Parkinson's disease; Type 2 diabetes mellitus

Most Recent Events

  • 10 Nov 2023 Pharmacodynamics data from a preclinical trial in Liver Injury presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 21 Jun 2023 Pharmacodynamics data from a preclinical studies in Hepatic fibrosis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
  • 21 Jun 2023 Pharmacodynamics data from a preclinical studies in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top